Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy

Ramin Sedaghat Herati, Van W. Knox, Patricia O'Donnell, Marina D'Angelo, Mark E. Haskins, Katherine P. Ponder

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Mucopolysaccharidosis I (MPS I) and MPS VII are due to deficient activity of the glycosaminoglycan-degrading lysosomal enzymes α-l-iduronidase and β-glucuronidase, respectively, and result in abnormal bones and joints. Here, the severity of skeletal disease in MPS I and MPS VII dogs and the effects of neonatal gene therapy were evaluated. For untreated MPS VII dogs, the lengths of the second cervical vertebrae (C2) and the femur were only 56% and 84% of normal, respectively, and bone dysplasia and articular erosions, and joint subluxation were severe. Previously, we reported that neonatal intravenous injection of a retroviral vector (RV) with the appropriate gene resulted in expression in liver and blood cells, and high serum enzyme activity. In this study, we demonstrate that C2 and femurs of RV-treated MPS VII dogs were longer at 82% and 101% of normal, respectively, and there were partial improvements of qualitative abnormalities. For untreated MPS I dogs, the lengths of C2 and femurs (91% and 96% of normal, respectively) were not significantly different from normal dogs. Qualitative changes in MPS I bones and joints were generally modest and were partially improved with RV treatment, although cervical spine disease was severe and was difficult to correct with gene therapy in both models. The greater severity of skeletal disease in MPS VII than in MPS I dogs may reflect accumulation of chondroitin sulfate in cartilage in MPS VII, or could relate to the specific mutations. Neonatal RV-mediated gene therapy ameliorates, but does not prevent, skeletal disease in MPS I and MPS VII dogs.

Original languageEnglish
Pages (from-to)142-151
Number of pages10
JournalMolecular genetics and metabolism
Issue number3
StatePublished - Nov 2008


  • Dysostosis multiplex
  • Gene therapy
  • Glycosaminoglycan
  • Lysosomal storage disease
  • Mucopolysaccharidosis
  • α-l-Iduronidase
  • β-glucuronidase


Dive into the research topics of 'Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy'. Together they form a unique fingerprint.

Cite this